Create Account | Sign In: Author or Forum

 
 
News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    
 

 Headlines:

 

Category: Endocrinology | Family Medicine | Internal Medicine | Nursing | Oncology | Pharmacy | Urology | Conference News

Back to Journal Articles

AACR: Metformin May Benefit Prostate Cancer Patients

Last Updated: April 02, 2012.

 

Metformin may improve prostate-specific antigen levels and slow cancer growth

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
The diabetes drug metformin is safe in men with prostate cancer undergoing prostatectomy, and may improve prostate-specific antigen levels and curb tumor growth, according to a phase II study presented at the annual meeting of the American Association for Cancer Research, held from March 31 to April 4 in Chicago.

MONDAY, April 2 (HealthDay News) -- The diabetes drug metformin is safe in men with prostate cancer undergoing prostatectomy, and may improve prostate-specific antigen levels and curb tumor growth, according to a phase II study presented at the annual meeting of the American Association for Cancer Research, held from March 31 to April 4 in Chicago.

Noting that previous studies have suggested that metformin may be beneficial against prostate cancer, Anthony M. Joshua, M.B.B.S., Ph.D., from the Princess Margaret Hospital in Toronto, and colleagues analyzed data from 22 men with confirmed prostate cancer who were assigned 500 mg metformin up to three times a day before undergoing prostatectomy.

During a median of 41 days of treatment, the researchers observed no grade 3 adverse events, and all men underwent radical prostatectomy with no adverse effects attributed to metformin. There were significant improvements in serum insulin growth factor 1, fasting glucose, body mass index, and waist-to-hip ratio. Prostate-specific antigen levels tended to improve (P = 0.08). No associations were noted between any metabolic, morphometric, or cancer-related serum indices.

"Although these are preliminary results, metformin appeared to reduce the growth rate of prostate cancer in a proportion of men," Joshua said in a statement. "This research builds on the hypothesis that metformin has a role in prostate cancer."

Abstract No. CT-04
More Information

Copyright © 2012 HealthDay. All rights reserved.


Previous: Inhibition of Immune Pathway May Trigger Melanoma Growth Next: AACR: Study Links Long-Term Estrogen Use to Breast Cancer

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.